Transgene (company) explained

Transgene S.A.
Type:Public (S.A.)
Foundation:December 1979
Location City:Illkirch-Graffenstaden
Location Country:France
Key People:Hedi Ben Brahim (President and CEO)

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer.

The company has two technological platforms based on these respective approaches: myvac (therapeutic vaccines) and Invir.IO (oncolytic viruses). Transgene’s portfolio consists of four products currently in clinical development.

Since January 2021, Hedi Ben Brahim has served as President and Chief Executive Officer of Transgene SA. The company is listed on the Paris Stock Exchange.[1] [2]

History

Transgene was founded in 1979, on the initiative of Pierre Chambon and Philippe Kourilsky. Jean-Pierre Lecocq was the first Scientific Director of Transgene in 1980.[3]

Technological platforms

Transgene owns two technological platforms:

Products in development

The Company has 4 clinical-stage products in its portfolio. These candidates are distinguished according to two product categories: therapeutic vaccines and oncolytic viruses.

• Therapeutic vaccines:

- “TG4001” is a therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus (human papillomavirus type 16).[10] It is currently in a Phase Ib/II clinical trial[11] evaluating TG4001 in combination with avelumab (in collaboration with Merck KGaA and Pfizer) in patients with advanced or metastatic HPV-16 positive cancers.[12]

- “TG4050” is an individualized immunotherapy from the myvac® platform. This candidate is currently evaluated in two Phase I clinical trials in ovarian cancer and Head and Neck cancer.[13] The trials are enrolling patients in the US, in France, and in the UK.[14]

• Oncolytic viruses

- “TG6002” is an oncolytic virus designed to express a recombinant enzyme within tumor cells capable of converting 5-FC (5-fluorocytosine) into 5-FU (5-fluorouracil), a chemotherapy agent.[15] The expression of this enzyme is enabled by the addition of the FCU1 gene into the viral DNA of TG6002.[16]

- “BT-001” is an oncolytic virus derived from Invir.IO™ platform.[17] It has been modified to encode the anti-CTLA4 antibody and the cytokine GM-CSF to target the tumor microenvironment. BT-001 is currently being evaluated in a Phase I/II clinical trial in solid tumors. [18] Transgene is collaborating with BioInvent for the development of this product.[19]

- Transgene and AstraZeneca have been collaborating since 2019 to co-develop oncolytic viruses from the Invir.IO™ platform.[20] [21] [22]

Management Committee

Transgene’s Management Committee is composed of the following members:

Notes and References

  1. Web site: Transgene. Euronext Live markets.
  2. Web site: CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant. 2021-09-26. BioCentury. en.
  3. Book: Lathe. Richard. The Early Development of the Vaccinia–Rabies Recombinant Vaccine Raboral®. Kieny. Marie Paule. 2021-04-26. IntechOpen. 978-1-83969-230-7. en.
  4. Foloppe . Johann . Kempf . Juliette . Futin . Nicolas . Kintz . Jacqueline . Cordier . Pascale . Pichon . Christelle . Findeli . Annie . Vorburger . Fabien . Quemeneur . Eric . Erbs . Philippe . The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism . Molecular Therapy - Oncolytics . September 2019 . 14 . 1–14 . 10.1016/j.omto.2019.03.005 . 31011628 . 6461584 .
  5. Gallardo . Franck . Schmitt . Doris . Brandely . Renée . Brua . Catherine . Silvestre . Nathalie . Findeli . Annie . Foloppe . Johann . Top . Sokunthea . Kappler-Gratias . Sandrine . Quentin-Froignant . Charlotte . Morin . Renaud . Lagarde . Jean-Michel . Bystricky . Kerstin . Bertagnoli . Stéphane . Erbs . Philippe . Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators . Biomedicines . 26 November 2020 . 8 . 12 . 543 . 10.3390/biomedicines8120543 . 33256205 . 7760631 . free .
  6. Kleinpeter . Patricia . Fend . Laetitia . Thioudellet . Christine . Geist . Michel . Sfrontato . Nathalie . Koerper . Véronique . Fahrner . Catherine . Schmitt . Doris . Gantzer . Murielle . Remy-Ziller . Christelle . Brandely . Renée . Villeval . Dominique . Rittner . Karola . Silvestre . Nathalie . Erbs . Philippe . Zitvogel . Laurence . Quéméneur . Eric . Préville . Xavier . Marchand . Jean-Baptiste . Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition . OncoImmunology . 2 October 2016 . 5 . 10 . e1220467 . 10.1080/2162402X.2016.1220467 . 27853644 . 5087307 .
  7. Web site: Transgene, NEC, BostonGene collaborate for ovarian and head & neck cancers trials. www.biospectrumasia.com.
  8. Bendjama . Kaïdre . Quemeneur . Eric . Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer . Human Vaccines & Immunotherapeutics . 2 September 2017 . 13 . 9 . 1997–2003 . 10.1080/21645515.2017.1334746 . 28846477 . 5612284 .
  9. Web site: NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC's AI and Transgene's myvac™ platform. NEC.
  10. Web site: TG4001 HPV Cancer Vaccine.
  11. Web site: In the clinic for March 11, 2021.
  12. Web site: Merck KGaA in Transgene cancer vaccine-checkpoint inhibitor test tie-up. 12 October 2016.
  13. Web site: In the clinic for June 28, 2021.
  14. Web site: Gamechanging 'vaccine for cancer' trial begins in Liverpool. 27 June 2021.
  15. Foloppe . Johann . Kempf . Juliette . Futin . Nicolas . Kintz . Jacqueline . Cordier . Pascale . Pichon . Christelle . Findeli . Annie . Vorburger . Fabien . Quemeneur . Eric . Erbs . Philippe . The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism . Molecular Therapy - Oncolytics . 27 September 2019 . 14 . 1–14 . 10.1016/j.omto.2019.03.005 . 31011628 . 6461584 .
  16. Foloppe . Johann . Kempf . Juliette . Futin . Nicolas . Kintz . Jacqueline . Cordier . Pascale . Pichon . Christelle . Findeli . Annie . Vorburger . Fabien . Quemeneur . Eric . Erbs . Philippe . The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism . Molecular Therapy - Oncolytics . 27 September 2019 . 14 . 1–14 . 10.1016/j.omto.2019.03.005 . 31011628 . 6461584 .
  17. Web site: First person enrolled in Phase I oncolytic virus trial.
  18. Web site: Regulatory actions for May 27, 2021.
  19. Web site: BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021.
  20. News: AstraZeneca ties up with France's Transgene to develop viral immunotherapies. Reuters. 2 May 2019.
  21. Web site: Transgene's armed oncolytic virus technology draws AZ in potential five-product deal.
  22. Web site: AstraZeneca adds oncolytic virus option through Transgene deal.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Transgene (company)".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.